Rhythm Pharmaceuticals amends bylaws to address universal proxy rules and enhance stockholder proposal disclosures

RHYTHM PHARMACEUTICALS, INC.

Amended and restated bylaws adopted by Board on Dec 14, 2023, effective same day.
Clarifies compliance with SEC Rule 14a-19 for proxy solicitations supporting director nominees.
Enhances disclosure requirements for stockholder nominations and other business proposals.
Requires any stockholder soliciting proxies to use a proxy card color other than white.
Deleted obsolete provisions and made technical, clarifying changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RHYTHM PHARMACEUTICALS, INC.: Amended and restated bylaws to adopt universal proxy rules, streamline stockholder nomination procedures, require white proxy card for soliciting stockholders, and delete obsolete provisions (effective 2023-12-14).

Change: bylaw amendment
Effective: 2023-12-14

Exact text from the filing

On December 14, 2023, the Board of Directors (the “ Board ”) of Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.

View on SEC.gov

Browse all governance changes →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-126873

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.